ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,033.11
0.94%
US Tech 100
21,360.00
1.34%
Dow Jones
42,515.09
0.75%
Brent Oil
72.02
-3.80%
Bitcoin
108,633.97
2.91%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Nurix Therapeutics Inc (NRIX) Quote

Nurix Therapeutics Inc

Nurix Therapeutics Inc (NRIX)

NASDAQ
11.91
-0.02
(-0.17%)
At close: June 16 4:00PM
15 min delayed - Upgrade to Realtime
11.91
0.00
( 0.00% )
After Hours: 4:00PM
15 min delayed - Upgrade to Realtime

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
11.91
Bid
11.68
Ask
12.35
Volume
553,953
11.46 Day's Range 11.97
8.18 52 Week Range 29.56
Market Cap
907.966M
Previous Close
11.93
Open
11.93
Last Trade
479
@
11.91
(priorref)
Last Trade Time
16:20:00
Financial Volume
$ 6,499,128
VWAP
11.7323
Average Volume (3m)
965,274
Shares Outstanding
76,235,594
Dividend Yield
-
PE Ratio
-4.69
Earnings Per Share (EPS)
-2.54
Revenue
54.55M
Net Profit
-193.57M

About Nurix Therapeutics Inc

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.nurixtx.com
Headquarters
Dover, Delaware, USA
Founded
-
Nurix Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRIX. The last closing price for Nurix Therapeutics was $11.93. Over the last year, Nurix Therapeutics shares have traded in a share price range of $ 8.18 to $ 29.56.

Nurix Therapeutics currently has 76,235,594 shares outstanding. The market capitalization of Nurix Therapeutics is $909.49 million. Nurix Therapeutics has a price to earnings ratio (PE ratio) of -4.69.

Ask ADVFN Intelligence (AI)

NRIX Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
June 12 2025
NRIX (-0.17%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
May 02 2025
NRIX (-0.17%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.1-8.4550345887813.0113.0911.6272533912.32387289CS
42.5727.51605995729.3413.099.2590060111.35396138CS
12-1.21-9.2225609756113.1213.578.1896527410.77740444CS
26-8.55-41.78885630520.4621.678.1888033913.84018CS
52-4.3-26.526835286916.2129.568.1886544418.23891628CS
1562.3524.58158995829.5629.564.2265386614.53629095CS
260-8.34-41.185185185220.2552.384.2254454517.69300804CS

NRIX - Frequently Asked Questions (FAQ)

What is the current Nurix Therapeutics share price?
The current share price of Nurix Therapeutics is $ 11.91
How many Nurix Therapeutics shares are in issue?
Nurix Therapeutics has 76,235,594 shares in issue
What is the market cap of Nurix Therapeutics?
The market capitalisation of Nurix Therapeutics is USD 909.49M
What is the 1 year trading range for Nurix Therapeutics share price?
Nurix Therapeutics has traded in the range of $ 8.18 to $ 29.56 during the past year
What is the PE ratio of Nurix Therapeutics?
The price to earnings ratio of Nurix Therapeutics is -4.69
What is the cash to sales ratio of Nurix Therapeutics?
The cash to sales ratio of Nurix Therapeutics is 16.65
What is the reporting currency for Nurix Therapeutics?
Nurix Therapeutics reports financial results in USD
What is the latest annual turnover for Nurix Therapeutics?
The latest annual turnover of Nurix Therapeutics is USD 54.55M
What is the latest annual profit for Nurix Therapeutics?
The latest annual profit of Nurix Therapeutics is USD -193.57M
What is the registered address of Nurix Therapeutics?
The registered address for Nurix Therapeutics is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the Nurix Therapeutics website address?
The website address for Nurix Therapeutics is www.nurixtx.com
Which industry sector does Nurix Therapeutics operate in?
Nurix Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JZJianzhi Education Technology Group Company Ltd
$ 5.7914
(102.50%)
2.36M
SLRXSalarius Pharmaceuticals Inc
$ 1.03
(64.77%)
8.33M
INEOINNEOVA Holdings Ltd
$ 1.61
(45.05%)
1.25M
TDTHTrident Digital Tech Holdings Ltd
$ 0.3199
(30.84%)
3.49M
RELIReliance Global Group Inc
$ 1.4799
(25.42%)
1.92M
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 1.10
(-19.79%)
172.24k
FTELFitell Corporation
$ 0.466
(-14.34%)
35.37k
AERTAeries Technology Inc
$ 0.861
(-13.03%)
38.65k
RUNSunrun Inc
$ 8.40
(-12.86%)
265.93k
SEDGSolarEdge Technologies Inc
$ 21.20
(-11.59%)
81.95k
GNLNGreenlane Holdings Inc
$ 0.0119
(-4.03%)
18.1M
HCTIHealthcare Triangle Inc
$ 0.0253
(-4.17%)
14.03M
SLRXSalarius Pharmaceuticals Inc
$ 1.03
(64.77%)
8.33M
SRMSRM Entertainment Inc
$ 8.87
(-3.48%)
4.25M
TDTHTrident Digital Tech Holdings Ltd
$ 0.3206
(31.12%)
3.49M

NRIX Discussion

View Posts
Monksdream Monksdream 8 months ago
NRIX 10Q due Oct 17
👍️0
Monksdream Monksdream 8 months ago
NRIX 10 Q due 10 October
👍️0
Monksdream Monksdream 9 months ago
NRIX creeping higher
👍️0
Monksdream Monksdream 11 months ago
NRIX 10 Q expected JULY11
👍️0
Monksdream Monksdream 12 months ago
NRIX new 52 week high
👍️0
Monksdream Monksdream 1 year ago
NRIX more new highs up ahead
👍️0
Monksdream Monksdream 1 year ago
NRIX new 52 hi
👍️0
Monksdream Monksdream 1 year ago
NRIX new 52 hi
👍️0
Monksdream Monksdream 1 year ago
NRIX new 52 week high
👍️0
TheFinalCD TheFinalCD 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/nurix-therapeutics-NRIX/stock-news/88898489/cathie-wood-doubles-down-on-these-2-strong-buy
👍️0
infamous infamous 4 years ago
what the F is wrong with this fkn stock? does it ever go up???
👍️0
Phosphene Phosphene 5 years ago
CEO: Dr. Arthur T. Sands

https://www.nurixtx.com/arthur-t-sands-m-d-ph-d/
👍️0
Phosphene Phosphene 5 years ago
Strategic partnerships with Sanofi and Gilead Sciences Inc.

https://www.nurixtx.com/research-development/strategic-partnerships/

Wellington and Baker Brothers are among Institutional Ownership and Shareholders:

https://fintel.io/so/us/nrix?__cf_chl_jschl_tk__=c9a7439112376e9f70de91c1316dfcc7e26d3519-1607403189-0-AT-0XpHMlNGWmcEzimwDKelDxLnOK6gsd8IihalGD8DcDe76KQlrWnh2Q1G3OLjfsidXSQyjVOkcCg3lXIXgKu6RIlw8DMusjRJpgnTzQP2qkahd1WSCP-5At2BI9Udfzc2vqpmlZOV3prAMIdFIh1_urJuBNq7hGlM4oSEJKFEFs8WDerUagukeDe9yBmvVg0Ne17vR8ByRaN-BlyHHxPWeTerJ_ZHoD1jnsxFYInhjhkK-XNkhe3BJ0Wzq3782kDVndNMNsb1glMkmm_NlSnc8Xbwve1nF3nGShcpgUxA-nefEgd9L74SzGXF1WftTIX4HYgwtb1BRzq82RClNfm9dr9Xb-hKp3xKKiYL4k9KfqV9OAePxDJoYgKqLUziXoA
👍️0
Phosphene Phosphene 5 years ago
Data support a planned clinical trial of NX-2127 in B-cell malignancies

http://www.globenewswire.com/news-release/2020/12/07/2140737/0/en/Nurix-Therapeutics-Presents-Preclinical-Data-at-62nd-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html
👍️0

Your Recent History

NASDAQ
NRIX
Nurix Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads